Genome-wide screening reveals producer-cell modifications that improve virus-like particle production and delivery potency
Authors:
Preprint
Abstract
Engineered virus-like particles (eVLPs) are promising vehicles for transient delivery of gene editing agents. While extensive particle engineering has yielded efficient eVLPs, it remains underexplored whether engineering the cells used to produce eVLPs could further improve eVLP properties. We developed a genome-wide screening approach to systematically investigate how genetic perturbations in producer cells influence eVLP production. This approach generates eVLPs loaded with guide RNAs that identify the genetic perturbation in the cell that produced a particular particle; the abundance of each guide RNA in eVLPs therefore reflects how the corresponding genetic perturbation influences eVLP production or cargo loading. We applied this approach to identify several genes that regulate eVLP cargo expression and loading into particles during the production process. Leveraging these insights, we engineered producer cells that support increased eVLP cargo packaging and a 2- to 9-fold increase in eVLP delivery potency across several cargo, particle, and target-cell types in cultured cells and in mice. Our findings suggest the potential of producer-cell engineering as a useful strategy for improving the utility of eVLPs and related delivery methods.Keywords
All Related Versions
- Published version: Nature Communications, 17 (1).
Funding Information
- Merkin Institute for Transformative Technologies in Healthcare
- McGuire Family Foundation
- James M. and Cathleen D. Stone Foundation
- Owens Family Foundation
- Valhalla Foundation
This publication has 54 references indexed in Scilit:
- Engineered nucleocytosolic vehicles for loading of programmable editorsCell, 2025
- The sound of silence: mechanisms and implications of HUSH complex functionTrends in Genetics, 2023
- Therapeutic in vivo delivery of gene editing agentsCell, 2022
- Engineered virus-like particles for efficient in vivo delivery of therapeutic proteinsCell, 2022
- Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineeringCell Reports, 2021
- Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for In Vivo CRISPR/Cas-Based Genome EditingACS Nano, 2020
- CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV VectorsCell, 2020
- VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9Molecular Therapy Nucleic Acids, 2018
- Molecular Basis of RNA Polymerase III Transcription Repression by Maf1Cell, 2010
- Mammalian Maf1 Is a Negative Regulator of Transcription by All Three Nuclear RNA PolymerasesMolecular Cell, 2007